摘要
目的观察瑞舒伐他汀治疗急性冠状动脉综合征(ACS)患者的治疗效果以及高敏C-反应蛋白(hs-CRP)水平。方法选择广东医学院附属医院和解放军92854部队医院收治的ACS患者207例,将其随机分为辛伐他汀组(65例)、10 mg瑞舒伐他汀组(67例)和20 mg瑞舒伐他汀组(75例),在常规治疗的基础上,分别观察服药2、4周的hs-CRP水平。结果三组服药前hs-CRP水平分别为(12.5±2.4)、(12.4±2.3)、(12.2±2.5)mg/L,差异无统计学意义(P>0.05)。三组患者服药2周后血清hs-CRP明显降低(P<0.05),分别为(10.6±2.5)、(9.9±2.4)、(8.6±2.3)mg/L,但三组间比较差异无统计学意义(P>0.05);服药4周后,20 mg瑞舒伐他汀组hs-CRP较辛伐他汀组及10 mg瑞舒伐他汀组hs-CRP浓度降低更明显,差异有统计学意义(P<0.05)。结论瑞舒伐他汀治疗可使ACS患者的hs-CRP水平明显降低,且高剂量瑞舒伐他汀抗炎效果更显著。
Objective To evaluate the effect of rosuvastatin on patients with acute coronary syndrome（ACS）and the change of levels of high-sensitive C-reactive protein（hs-CRP）. Methods Two hundred and seven patients with ACS of Guangdong Medical College affiliated hospital and 92003 Army Health Care Clinics of PLA were selected randomly divided into three groups：simvastatin treatment group（n = 65）,10 mg rosuvastatin treatment group（n = 67）and 20 mg rosuvastatin treatment group（n =75）. Based on routine treatment,simvastatin or rosuvastatin were added,and the levels of hs-CRP were observed after 2 weeks and 4 weeks treatment. Results The differences of the hs-CRP levels among the three groups before treatment were not signifi-cant（P 〉 0. 05）,which were（12. 5 ± 2. 4）,（12. 4 ± 2. 3）and（12. 2 ± 2. 5）mg/ L respectively. After added simvastatin or rosuv-astatin for 2 weeks,the level of hs-CRP significantly reduced（P 〈 0. 05）,（10. 6 ± 2. 5）,（9. 9 ± 2. 4）and（8. 6 ± 2. 3）mg/ L re-spectively,but there were no significant differences among the three groups. After added simvastatin or rosuvastatin for 4 weeks, the hs-CRP level of the 20 mg rosuvastatin groups were significantly lower than the others（P 〈 0. 05）. Conclusion Treatment with high does rosuvastatin（20 mg）can reduce the hs-CRP level,and improve the function of the vascular endothelium,which may promote the stabilization of atherosclerotic plaque.
出处
《临床医学》
CAS
2014年第11期13-14,共2页
Clinical Medicine
